Journal of Clinical Medicine of Kazakhstan

Number (3) 53, 2019

J Clin Med Kaz 2019;2(52):6-9 doi:10.23950/1812-2892-JCMK-00674
Value of vascular growth factors after stenting coronary arteries in patients with IHD

Authors: Dana Taizhanova, Roza Bodaubay

Abstract

View in PDF

Number of views: 161

One of the most important achievements of medical science is the development and implementation of endovascular methods for treating ischemic heart disease, the volume of which is progressively increasing in relation to other methods of myocardial revascularization. As a result of data from various researchers, the mechanism for the development of coronary artery restenosis in patients with coronary artery disease undergoing endovascular interventions can be an inflammatory reaction, smooth muscle hyperplasia, formation of a wall clot and its organization, as well as the effect of an angiotensin-converting enzyme that activates angiotensin-II, an inducer and inhibits the activity of bradykinin, which inhibits cell growth. Recent studies of molecular and cellular mechanisms of restenosis in models of vascular damage in animals, as well as histological studies of human coronary arteries, have shown that the basis for the development of restenosis is the activation of migration and proliferation of vascular cells under the influence of growth factors caused by damage, which is a manifestation of angiogenesis and leads to neointima hyperplasia and neoadvention, narrowing the lumen of arteries. However, today there is no single point of view regarding the role of vascular growth factors in the development of the restenotic process, the number of studies highlighting the dynamics of the concentration of vascular growth factors in response to balloon expansion or implantation of coronary stents, and their possible role in the neointima formation and the restenosis development.

J Clin Med Kaz 2019;2(52):23-29 doi:10.23950/1812-2892-JCMK-00677
Determination of cytokine profile and fecal calprotectin in patients with inflammatory bowel disease of different activity degree

Authors: Ainur Doszhan, Roza Bektayeva, Aiman Galiyeva, Kapura Adrissova

Abstract

View in PDF

Number of views: 147

Aim: To determine the IL-6, IL-8, TNF-α and fecal calprotectin levels in different phases of the disease and correlate their values with the clinical and endoscopic data in patients with inflammatory bowel diseases. Methods: 41 patients with IBD were selected: 78% with ulcerative colitis and 22% with Crohn's disease, 39% women and 61% men, mean age 35,3±1,9. Ulcerative colitis: acute current – 12,5%, chronic continuous – 6,25%, chronic relapsing – 62,5%, rarely relapsing – 12,5%, often relapsing – 6,25%. Minimal activity – 15,6%, moderate activity – 84,4%. Crohn's disease depending on the Crohn's Disease Activity Index (CDAI): mild disease and minimal activity – 55,6%, moderate severity and moderate activity – 44,4%. Results: IL-6 was increased to 20,56±5,51 pg/ml at ulcerative colitis, to 18,64±4,70 pg/ml at Crohn's disease; IL-8 – 79,38±15,37 pg/ml at ulcerative colitis and 82,49±34,81 pg/ml at Crohn's disease; TNF-α – 28,70±3,24 pg/ml and 32,32±6,92 pg/ml, respectively. Depending on the extent of the lesion: for IL-6 at E2 – 23,91±14,64 pg/ml and at E3 – 20,54±5,61 pg/ml; for IL-8 at E2 – 60,95±14,60 pg/ml and at E3 – 97,31±24,10 pg/ml. Conclusion: The results of the study have demonstrated an increase in the concentrations of IL-6, IL-8 and TNF-α in patients with ulcerative colitis and Crohn's disease, significantly exceeding the reference values. With increased activity of the inflammatory process, a significant raise in IL-6, IL-8 and TNF-α level was observed. Determining the level of fecal calprotectin depending on the location of the lesion and the activity of the process confirmed its importance in assessing the extent of lesions of the colon and diagnosing the activity of ulcerative colitis and Crohn's disease in different phases of the disease.